Navigation Links
Beta-Blockers Should Not Be First Choice for High Blood Pressure

Beta-blocker drugs such as Tenormin, Inderal and Lopressor should not be a doctor’s first choice for treating high blood pressure//, according to a large new review of studies.

The review, coming on the heels of several similar large reviews, found that beta-blocker users have a slightly higher risk of death and cardiovascular disease than patients who use calcium channel blockers such as Norvasc and Cardizem to manage their blood pressure.

Patients who take diuretics such as hydrochlorothiazide or a group of drugs called RAS inhibitors (brand names include Altace, Lotensin, and Cozaar) have risks similar to those taking beta-blockers.

Dr. Charles Shey Wiysonge of the Ministry of Public Health in Cameroon, who led the new review, said many recent reviews “arrived at similar conclusions — that the available evidence does not support the use of beta-blockers as first-line drugs in the treatment of hypertension.”

The review appears in the latest issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

Wiysonge said the Cochrane review is different from other recent reviews because it compares beta-blockers head-to-head against specific antihypertensive medications, rather than comparing beta-blockers against all other high blood pressure medicines as a group.

After combing through 13 studies of 91,561 patients, Wiysonge and colleagues found no difference in the risk of death or cardiovascular disease among those who used beta-blockers, diuretics and RAS inhibitor drugs.

However, the absolute risk of death was a half-percent greater among beta-blocker users compared to those taking calcium channel blockers.

In addition, patients taking beta-blockers had a 1.3 percent increase in the risk of cardiovascular disease — mostly strokes — compared to those taking calcium channel blockers.

Also, “patients who used beta-blockers were more likely to experience undesirable effects and abandon their antihypertension medications” compared to patients who took diuretics or RAS inhibitors, Wiysonge said.

A review of 22 studies published in the medical journal The Lancet in January may suggest another reason to be wary of beta-blockers for high blood pressure. The review concluded that diuretics and beta-blocker treatments may increase the chances of developing type 2 diabetes.

Lancet author Dr. William Elliott of Rush University Medical Center in Chicago said antihypertensive drugs such as ACE inhibitors and angiotensin receptor blockers — types of RAS drugs — were associated with the lowest risk of developing diabetes.

Source-Newswie
SRM
'"/>




Related medicine news :

1. Beta-Blockers Should Be the Second Line of Treatment
2. Babies Should Get Vitamin D Supplement
3. How Much Should Athletes Drink?
4. Angioplasty Should be the Standard
5. Parents Should Look For Signs Of Children Becoming Overweight
6. Diabetics Should Adopt Better Preventive Measures
7. Before Weight Loss Surgery One Should Get Tested for Bacteria
8. Should we avoid energy drinks to protect our teeth?
9. Parents Should Beware of Violent Video Games
10. Exercises Should Be Recommended During Pregnancy
11. Khushboo Should ‘Talk about Safe Sex’ and not ‘ Premarital Sex’ Says Miniter
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... N.Y (PRWEB) , ... October 13, 2017 , ... Lori ... became a member of ElderCounsel, a national organization of elder law and special needs ... changing laws and rules. It also provides a forum to network with elder law ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology: